1. Home
  2. KRMD vs KPTI Comparison

KRMD vs KPTI Comparison

Compare KRMD & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KORU Medical Systems Inc. (DE)

KRMD

KORU Medical Systems Inc. (DE)

HOLD

Current Price

$6.54

Market Cap

186.3M

Sector

Health Care

ML Signal

HOLD

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$7.47

Market Cap

94.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRMD
KPTI
Founded
1980
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
186.3M
94.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
KRMD
KPTI
Price
$6.54
$7.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
6
Target Price
$5.88
$22.17
AVG Volume (30 Days)
215.8K
219.5K
Earning Date
11-12-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$39,070,637.00
$142,530,000.00
Revenue This Year
$23.36
$3.82
Revenue Next Year
$18.63
N/A
P/E Ratio
N/A
N/A
Revenue Growth
22.12
N/A
52 Week Low
$1.86
$3.51
52 Week High
$6.61
$12.45

Technical Indicators

Market Signals
Indicator
KRMD
KPTI
Relative Strength Index (RSI) 74.17 66.65
Support Level $5.48 $5.99
Resistance Level $5.88 $7.70
Average True Range (ATR) 0.34 0.53
MACD 0.02 0.13
Stochastic Oscillator 89.42 88.53

Price Performance

Historical Comparison
KRMD
KPTI

About KRMD KORU Medical Systems Inc. (DE)

KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: